{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:11:53Z","timestamp":1792685513469,"version":"4.5.0"},"reference-count":187,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Breast cancer remains a leading cause of mortality among women worldwide, presenting significant treatment challenges due to its aggressive nature and lack of targeted therapies. Traditional treatments, including surgery, radiation, and chemotherapy, have improved survival rates. However, limitations such as drug resistance and adverse side effects persist. Recent advancements in nanotechnology offer promising avenues for enhancing breast cancer treatment by improving drug delivery, increasing therapeutic efficacy, and minimizing systemic toxicity. This review explores breast cancer\u2019s pathophysiology and molecular mechanisms, evaluates current diagnostic and therapeutic strategies, and discusses emerging innovations in nanotechnology and integrative medicine. Recent studies have demonstrated the efficacy of green nanotechnology in transforming Ayurvedic medicine into scientifically credible treatments. These integrative approaches not only enhance the therapeutic potential of traditional medicine but also offer a pathway to overcome challenges associated with conventional cancer treatments. The convergence of nanotechnology and traditional medical systems holds transformative potential in breast cancer therapy. By leveraging the unique properties of nanoparticles and nanorobotics, it is possible to develop more effective, personalized, and less toxic treatment modalities. Future research should optimize these integrative approaches, conduct rigorous clinical trials, and elucidate the underlying mechanisms to fully realize their potential in combating breast cancer.<\/jats:p>","DOI":"10.3390\/ijms27052109","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T15:05:27Z","timestamp":1771945527000},"page":"2109","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Future of Breast Cancer Treatment: From Conventional Wisdom to Nanotechnology-Enabled Precision"],"prefix":"10.3390","volume":"27","author":[{"given":"Neetika","family":"Kimta","sequence":"first","affiliation":[{"name":"School of Biological and Environmental Sciences, Shoolini University of Biotechnology and Management Sciences, Solan 173229, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak A.","family":"Majdalawieh","sequence":"additional","affiliation":[{"name":"Department of Biology, Chemistry and Environmental Sciences, College of Arts and Sciences, American University of Sharjah, Sharjah P.O. Box 26666, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-1057","authenticated-orcid":false,"given":"Amin F.","family":"Majdalawieh","sequence":"additional","affiliation":[{"name":"Department of Biology, Chemistry and Environmental Sciences, College of Arts and Sciences, American University of Sharjah, Sharjah P.O. Box 26666, United Arab Emirates"},{"name":"Advanced Biosciences and Bioengineering Research Center, American University of Sharjah, Sharjah P.O. Box 26666, United Arab Emirates"},{"name":"Bioinformatics and Computational Biology Research Group, American University of Sharjah, Sharjah P.O. Box 26666, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.2147\/IJN.S140325","article-title":"Drug delivery approaches for breast cancer","volume":"12","author":"Singh","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jconrel.2018.10.030","article-title":"Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer","volume":"291","author":"Greish","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e000208","DOI":"10.1136\/esmoopen-2017-000208","article-title":"How many diseases is triple negative breast cancer: The protagonism of the immune microenvironment","volume":"2","author":"Saraiva","year":"2017","journal-title":"ESMO Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1038\/s41467-018-06893-9","article-title":"Collagen prolyl 4-hydroxylase 1 is essential for HIF-1\u03b1 stabilization and TNBC chemoresistance","volume":"9","author":"Xiong","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"BSR20171357","DOI":"10.1042\/BSR20171357","article-title":"Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer","volume":"38","author":"Pakala","year":"2018","journal-title":"Biosci. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/j.clbc.2017.07.013","article-title":"Alarming burden of triple-negative breast cancer in India","volume":"18","author":"Thakur","year":"2018","journal-title":"Clin. Breast Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"ref_8","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jncimono\/1997.22.79","article-title":"Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: Comparison of relative and absolute benefit","volume":"1997","author":"Kerlikowske","year":"1997","journal-title":"JNCI Monogr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addr.2012.09.006","article-title":"Nanoparticles in cancer therapy and diagnosis","volume":"64","author":"Brigger","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","article-title":"Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications","volume":"200","author":"Wicki","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature17038","article-title":"Metastatic colonization by circulating tumour cells","volume":"529","author":"Obenauf","year":"2016","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.addr.2008.08.005","article-title":"Active targeting schemes for nanoparticle systems in cancer therapeutics","volume":"60","author":"Byrne","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1242\/jcs.01000","article-title":"The stroma as a crucial target in rat mammary gland carcinogenesis","volume":"117","author":"Maffini","year":"2004","journal-title":"J. Cell Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.pbiomolbio.2016.07.004","article-title":"Carcinogenesis explained within the context of a theory of organisms","volume":"122","author":"Sonnenschein","year":"2016","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"a027128","DOI":"10.1101\/cshperspect.a027128","article-title":"The Cellular origin and evolution of breast cancer","volume":"7","author":"Zhang","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.stem.2010.07.010","article-title":"BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells","volume":"7","author":"Molyneux","year":"2010","journal-title":"Cell Stem Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1158\/0008-5472.CAN-15-3490","article-title":"Cancer stem cells regulate cancer-associated fibroblasts via activation of hedgehog signaling in mammary gland tumors","volume":"77","author":"Valenti","year":"2017","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/path.2808","article-title":"The molecular pathology of breast cancer progression","volume":"223","author":"Bombonati","year":"2011","journal-title":"J. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature11143","article-title":"Whole-genome analysis informs breast cancer response to aromatase inhibition","volume":"486","author":"Ellis","year":"2012","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2559.2010.03568.x","article-title":"Breast cancer precursors revisited: Molecular features and progression pathways","volume":"57","author":"Geyer","year":"2010","journal-title":"Histopathology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature17676","article-title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences","volume":"534","author":"Davies","year":"2016","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1158\/1078-0432.CCR-16-2548","article-title":"Translational genomics: Practical applications of the genomic revolution in breast cancer","volume":"23","author":"Yates","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.drudis.2019.02.003","article-title":"Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents","volume":"24","author":"Ediriweera","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_25","first-page":"370","article-title":"Oestrogen receptors in breast cancer: Basic mechanisms and clinical implications","volume":"7","author":"Williams","year":"2013","journal-title":"Ecancermedicalscience"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10549-007-9618-4","article-title":"Estrogen receptors outside the nucleus in breast cancer","volume":"108","author":"Levin","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Nagarajan, D., and McArdle, S.E. (2018). Immune landscape of breast cancers. Biomedicines, 6.","DOI":"10.3390\/biomedicines6010020"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1073\/pnas.1104303108","article-title":"Leukocyte composition of human breast cancer","volume":"109","author":"Ruffell","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: From TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1604700","article-title":"Extending aromatase-inhibitor adjuvant therapy to 10 years","volume":"375","author":"Goss","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2013.31.18_suppl.5","article-title":"aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer","volume":"31","author":"Gray","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejca.2017.01.017","article-title":"Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)","volume":"75","author":"Duffy","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/0008-5472.CAN-11-3364","article-title":"19p13. 1 is a triple-negative\u2013specific breast cancer susceptibility locus","volume":"72","author":"Stevens","year":"2012","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer","volume":"358","author":"Sparano","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa0910320","article-title":"Adjuvant docetaxel for high-risk, node-negative breast cancer","volume":"363","author":"Ruiz","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.suc.2013.01.005","article-title":"Genetic predisposition syndromes and their management","volume":"93","author":"Euhus","year":"2013","journal-title":"Surg. Clin. N. Am."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2018.03.015","article-title":"Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort","volume":"96","author":"Gobbini","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1158\/1055-9965.EPI-16-0889","article-title":"Estimation of the number of women living with metastatic breast cancer in the United States","volume":"26","author":"Mariotto","year":"2017","journal-title":"Cancer Epidemiol. Prev. Biomark."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10654-013-9816-9","article-title":"Effect of mammography screening on surgical treatment for breast cancer: A nationwide analysis of hospitalization rates in Germany 2005\u20132009","volume":"28","author":"Stang","year":"2013","journal-title":"Eur. J. Epidemiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"d4692","DOI":"10.1136\/bmj.d4692","article-title":"Effect of mammography screening on surgical treatment for breast cancer in Norway: Comparative analysis of cancer registry data","volume":"343","author":"Suhrke","year":"2011","journal-title":"BMJ"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1200\/JCO.2014.56.6232","article-title":"Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age \u2265 50 years: Evidence from an individual patient data meta-analysis","volume":"33","author":"Phi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1054\/brst.2001.0409","article-title":"Evidence relevant to the investigation of breast symptoms: The triple test","volume":"11","author":"Irwig","year":"2002","journal-title":"Breast"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/SLA.0b013e31821f1564","article-title":"Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: Meta-analysis of its accuracy and utility in staging the axilla","volume":"254","author":"Houssami","year":"2011","journal-title":"Ann. Surg."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/S0140-6736(11)61350-0","article-title":"MRI for breast cancer screening, diagnosis, and treatment","volume":"378","author":"Morrow","year":"2011","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ejca.2010.02.015","article-title":"Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working group","volume":"46","author":"Sardanelli","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10549-017-4325-2","article-title":"Family history and risk of breast cancer: An analysis accounting for family structure","volume":"165","author":"Brewer","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Dall, G.V., and Britt, K.L. (2017). Estrogen effects on the mammary gland in early and late life and breast cancer risk. Front. Oncol., 7.","DOI":"10.3389\/fonc.2017.00110"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/IJWH.S129017","article-title":"Reproductive and hormonal risk factors of breast cancer: A historical perspective","volume":"9","author":"Horn","year":"2017","journal-title":"Int. J. Women\u2019s Health"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-013-2531-0","article-title":"Reproductive factors and the risk of breast cancer in old age: A Norwegian cohort study","volume":"139","author":"Horn","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(13)70301-2","article-title":"Sex hormones and risk of breast cancer in premenopausal women: A collaborative reanalysis of individual participant data from seven prospective studies","volume":"14","author":"Hormones","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0140-6736(07)60534-0","article-title":"Ovarian cancer and hormone replacement therapy in the Million Women Study","volume":"369","author":"Beral","year":"2007","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nrclinonc.2011.110","article-title":"Hormone replacement therapy and the risk of breast cancer","volume":"8","author":"Narod","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","article-title":"Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial","volume":"49","author":"Fornander","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1146\/annurev-nutr-112912-095300","article-title":"Dietary fat in breast cancer survival","volume":"33","author":"Makarem","year":"2013","journal-title":"Annu. Rev. Nutr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","article-title":"Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18","volume":"2001","author":"Wolmark","year":"2001","journal-title":"JNCI Monogr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2\u20133 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1200\/JCO.2007.11.6798","article-title":"Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen","volume":"26","author":"Goss","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_59","first-page":"2747","article-title":"Breast International Group (BIG) 1\u201398 Col-laborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"354","author":"Keshaviah","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2217\/fon.12.49","article-title":"The BOLERO-2 trial: The addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer","volume":"8","author":"Beaver","year":"2012","journal-title":"Futur. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Aebi, S., Gelber, S., L\u00e1ng, I., Anderson, S., Robidoux, A., Mart\u00edn, M., Nortier, J., Mamounas, E., Geyer, C., and Maibach, R. (2012). Abstract S3-2: Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27\u201302, NSABP B-37, BIG 1\u201302). Cancer Res., 72.","DOI":"10.1158\/0008-5472.SABCS12-S3-2"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa022152","article-title":"Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer","volume":"347","author":"Fisher","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3747\/co.25.3729","article-title":"Clinical practice guidelines in breast cancer","volume":"25","author":"Tyagi","year":"2018","journal-title":"Curr. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","article-title":"Axillary nodal management following neoadjuvant chemotherapy: A review","volume":"3","author":"Pilewskie","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc1566","article-title":"Cancer nanotechnology: Opportunities and challenges","volume":"5","author":"Ferrari","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_70","first-page":"1124","article-title":"Final in-line filtration: Removal of contaminants from IV fluids and drugs","volume":"18","author":"Rapp","year":"1983","journal-title":"Hosp. Formul."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00126839-200506020-00002","article-title":"Acute toxicity of intravenously administered microfabricated silicon dioxide drug delivery particles in mice: Preliminary findings","volume":"6","author":"Martin","year":"2005","journal-title":"Drugs RD"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1073\/pnas.0610298104","article-title":"Biomimetic amplification of nanoparticle homing to tumors","volume":"104","author":"Simberg","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ijpharm.2004.12.021","article-title":"Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice","volume":"293","author":"Bibby","year":"2005","journal-title":"Int. J. Pharm."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nm0603-685","article-title":"Molecular regulation of vessel maturation","volume":"9","author":"Jain","year":"2003","journal-title":"Nat. Med."},{"key":"ref_75","first-page":"265","article-title":"Microvascular architecture in a mammary carcinoma: Branching patterns and vessel dimensions","volume":"51","author":"Less","year":"1991","journal-title":"Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/B:BREA.0000004371.48757.19","article-title":"Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2\/HER2","volume":"82","author":"Azemar","year":"2003","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc1456","article-title":"High interstitial fluid pressure\u2014An obstacle in cancer therapy","volume":"4","author":"Heldin","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_78","first-page":"4478","article-title":"Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: Implications for therapy","volume":"50","author":"Boucher","year":"1990","journal-title":"Cancer Res."},{"key":"ref_79","first-page":"4251","article-title":"Oncotic pressure in solid tumors is elevated","volume":"60","author":"Stohrer","year":"2000","journal-title":"Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF03187139","article-title":"Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma","volume":"1","author":"Nathanson","year":"1994","journal-title":"Ann. Surg. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.2005.08.119","article-title":"Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: Clinical implications","volume":"23","author":"Taghian","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1021\/nl070610y","article-title":"Near-infrared resonant nanoshells for combined optical imaging and photothermal cancer therapy","volume":"7","author":"Gobin","year":"2007","journal-title":"Nano Lett."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0002-9440(10)65006-7","article-title":"Openings between defective endothelial cells explain tumor vessel leakiness","volume":"156","author":"Hashizume","year":"2000","journal-title":"Am. J. Pathol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1567-5769(02)00271-0","article-title":"Vascular permeability enhancement in solid tumor: Various factors, mechanisms involved and its implications","volume":"3","author":"Maeda","year":"2003","journal-title":"Int. Immunopharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.20031256","article-title":"Phagocytosis, innate immunity, and host\u2013pathogen specificity","volume":"199","author":"Henneke","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_86","first-page":"8","article-title":"Nanotechnology","volume":"1","author":"Theis","year":"2006","journal-title":"Nat. Nano."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.8-suppl_2-3","article-title":"Liposomal anthracyclines in metastatic breast cancer: Clinical update","volume":"8","author":"Rivera","year":"2003","journal-title":"Oncologist"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"8156","DOI":"10.1158\/0008-5472.CAN-06-4762","article-title":"Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system","volume":"67","author":"Pan","year":"2007","journal-title":"Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1021\/nl050127s","article-title":"Immunotargeted nanoshells for integrated cancer imaging and therapy","volume":"5","author":"Loo","year":"2005","journal-title":"Nano Lett."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1166\/jnn.2004.074","article-title":"Synthesis and characterization of silica-embedded iron oxide nanoparticles for magnetic resonance imaging","volume":"4","author":"Yan","year":"2004","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/320134a0","article-title":"Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A","volume":"320","author":"Green","year":"1986","journal-title":"Nature"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.electacta.2016.03.198","article-title":"Highly water-soluble and surface charge-tunable fluorescent fullerene nanoparticles: Facile fabrication and cellular imaging","volume":"201","author":"Xie","year":"2016","journal-title":"Electrochim. Acta"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1703036","DOI":"10.1002\/adfm.201703036","article-title":"Targeted delivery of CRISPR\/Cas9-mediated cancer gene therapy via liposome-templated hydrogel nanoparticles","volume":"27","author":"Chen","year":"2017","journal-title":"Adv. Funct. Mater."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijpharm.2017.06.026","article-title":"In vitro studies of phospholipid-modified PAMAM-siMDR1 complexes for the reversal of multidrug resistance in human breast cancer cells","volume":"530","author":"Liu","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1021\/nn3044066","article-title":"Codelivery of an optimal drug\/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo","volume":"7","author":"Meng","year":"2013","journal-title":"ACS Nano"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3109\/10717544.2013.834412","article-title":"Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells","volume":"20","year":"2013","journal-title":"Drug Deliv."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1158\/0008-5472.CAN-14-3485","article-title":"Silencing \u03b23 integrin by targeted ECO\/siRNA nanoparticles inhibits EMT and metastasis of triple-negative breast cancer","volume":"75","author":"Parvani","year":"2015","journal-title":"Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.colsurfb.2013.08.032","article-title":"Quercetin-nanostructured lipid carriers: Characteristics and anti-breast cancer activities in vitro","volume":"113","author":"Sun","year":"2014","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1039\/c1nr10573f","article-title":"Inhibiting metastasis of breast cancer cells in vitro using gold nanorod-siRNA delivery system","volume":"3","author":"Zhang","year":"2011","journal-title":"Nanoscale"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.nano.2013.10.006","article-title":"A rationally designed photo-chemo core-shell nanomedicine for inhibiting the migration of metastatic breast cancer cells followed by photodynamic killing","volume":"10","author":"Malarvizhi","year":"2014","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jconrel.2014.11.011","article-title":"Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells","volume":"205","author":"Li","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/2211550104666151008213153","article-title":"Nanoparticle coated viral vectors for gene therapy","volume":"5","author":"Selot","year":"2016","journal-title":"Curr. Biotechnol."},{"key":"ref_103","first-page":"78","article-title":"Co-delivery of resveratrol and docetaxel via polymeric micelles to improve the treatment of drug-resistant tumors","volume":"14","author":"Guo","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4172\/2157-7439.1000390","article-title":"Gloriosa superba mediated synthesis of silver and gold na-noparticles for anticancer applications","volume":"7","author":"Ghosh","year":"2016","journal-title":"J. Nanomed. Nanotechnol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.fjps.2018.06.001","article-title":"Anticancer effects of silver nanoparticles encapsulated by Gloriosa superba (L.) leaf extracts in DLA tumor cells","volume":"4","author":"Muthukrishnan","year":"2018","journal-title":"Future J. Pharm. Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1038\/ncomms6988","article-title":"Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor","volume":"6","author":"Liu","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.addr.2012.07.018","article-title":"Mesoporous silica nanoparticles in medicine\u2014Recent advances","volume":"65","author":"Mamaeva","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.omtn.2017.03.007","article-title":"Stimuli-responsive mesoporous silica NPs as non-viral dual siRNA\/chemotherapy carriers for triple negative breast cancer","volume":"7","author":"Darvishi","year":"2017","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/10717540902937562","article-title":"Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells","volume":"16","author":"Kang","year":"2009","journal-title":"Drug Deliv."},{"key":"ref_110","first-page":"65","article-title":"Liposomes as targetable drug carriers","volume":"2","author":"Torchilin","year":"1985","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Gurunathan, S., Kang, M.-H., Qasim, M., and Kim, J.-H. (2018). Nanoparticle-mediated combination therapy: Two-in-one approach for cancer. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19103264"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.biomaterials.2014.12.030","article-title":"Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery","volume":"45","author":"Gu","year":"2015","journal-title":"Biomaterials"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Palmerston Mendes, L., Pan, J., and Torchilin, V.P. (2017). Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules, 22.","DOI":"10.3390\/molecules22091401"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.18632\/oncotarget.3348","article-title":"Graphene oxide selectively targets cancer stem cells, across multiple tumor types: Implications for non-toxic cancer treatment, via \u201cdifferentiation-based nano-therapy\u201d","volume":"6","author":"Fiorillo","year":"2015","journal-title":"Oncotarget"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.biomaterials.2011.12.052","article-title":"The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy","volume":"33","author":"Burke","year":"2012","journal-title":"Biomaterials"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1705737","DOI":"10.1002\/adma.201705737","article-title":"In situ shRNA synthesis on DNA\u2013polylactide nanoparticles to treat multidrug resistant breast cancer","volume":"30","author":"Ni","year":"2018","journal-title":"Adv. Mater."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.amjms.2017.08.002","article-title":"Novel survivin-targeted small interfering RNA delivered by nanoparticles","volume":"354","author":"Feng","year":"2017","journal-title":"Am. J. Med. Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jconrel.2012.08.020","article-title":"Overcoming drug resistance of MCF-7\/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex","volume":"163","author":"Han","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Manju, S., and Sreenivasan, K. (2010). Functionalised nanoparticles for targeted drug delivery. Biointegration of Medical Implant Materials, Elsevier.","DOI":"10.1533\/9781845699802.2.267"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1517\/17425241003777010","article-title":"Gold nanoparticles: Opportunities and challenges in nanomedicine","volume":"7","author":"Arvizo","year":"2010","journal-title":"Expert. Opin. Drug Deliv."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jcis.2017.10.030","article-title":"Targeted photodynamic therapy of breast cancer cells using lactose-phthalocyanine functionalized gold nanoparticles","volume":"512","author":"Calavia","year":"2018","journal-title":"J. Colloid Interface Sci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/aps.2011.82","article-title":"Gold nanoparticles in cancer therapy","volume":"32","author":"Lim","year":"2011","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.colsurfb.2012.02.039","article-title":"The anticancer activity of chloroquine-gold nanoparticles against MCF-7 breast cancer cells","volume":"95","author":"Joshi","year":"2012","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Licciardi, M., Volsi, A.L., Mauro, N., Scialabba, C., Cavallaro, G., and Giammona, G. (2016). Preparation and characterization of inulin coated gold nanoparticles for selective delivery of doxorubicin to breast cancer cells. J. Nanomater., 2016.","DOI":"10.1155\/2016\/2078315"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4172\/2157-7439.1000103e","article-title":"Targeted nanoparticles for cancer therapy: Promises and challenges","volume":"2","author":"Nguyen","year":"2011","journal-title":"J. Nanomed. Nanotechnol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.msec.2016.11.065","article-title":"Development and evaluation of targeting ligands surface modified paclitaxel nanocrystals","volume":"72","author":"Sohn","year":"2017","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Tenzer, S., Docter, D., Kuharev, J., Musyanovych, A., Fetz, V., Hecht, R., Schlenk, F., Fischer, D., Kiouptsi, K., and Reinhardt, C. (2020). Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nano-Enabled Medical Applications, Jenny Stanford Publishing.","DOI":"10.1201\/9780429399039-9"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nmat2442","article-title":"Understanding biophysicochemical interactions at the nano\u2013bio interface","volume":"8","author":"Nel","year":"2009","journal-title":"Nat. Mater."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2010.01.036","article-title":"Endocytosis of nanomedicines","volume":"145","author":"Sahay","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nnano.2012.237","article-title":"Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface","volume":"8","author":"Salvati","year":"2013","journal-title":"Nat. Nanotechnol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1038\/nprot.2014.139","article-title":"Quantitative profiling of the protein coronas that form around nanoparticles","volume":"9","author":"Docter","year":"2014","journal-title":"Nat. Protoc."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"R\u00f6cker, C., P\u00f6tzl, M., Zhang, F., Parak, W.J., and Nienhaus, G.U. (2024). A Quantitative Fluorescence Study of Protein Monolayer Formation on Colloidal Nanoparticles. Bio-Nano Interfaces, Jenny Stanford Publishing.","DOI":"10.1201\/9781003306498-32"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nnano.2012.212","article-title":"Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions","volume":"8","author":"Parodi","year":"2013","journal-title":"Nat. Nanotechnol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1172\/JCI31422","article-title":"Altered macrophage differentiation and immune dysfunction in tumor development","volume":"117","author":"Sica","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1021\/ja300537u","article-title":"A chemical approach for cell-specific targeting of nanomaterials: Small-molecule-initiated misfolding of nanoparticle corona proteins","volume":"134","author":"Prapainop","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s10549-011-1411-8","article-title":"Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib","volume":"132","author":"Kaklamani","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Moreira, R., Granja, A., Pinheiro, M., and Reis, S. (2021). Nanomedicine interventions in clinical trials for the treatment of metastatic breast cancer. Appl. Sci., 11.","DOI":"10.3390\/app11041624"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10549-012-2341-9","article-title":"Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen","volume":"137","author":"Yardley","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.clbc.2014.02.005","article-title":"Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer","volume":"14","author":"Layman","year":"2014","journal-title":"Clin. Breast Cancer"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/jco.2011.29.15_suppl.1126","article-title":"Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735","volume":"29","author":"Northfelt","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.clbc.2013.08.003","article-title":"Nab-paclitaxel\/bevacizumab\/carboplatin chemotherapy in first-line triple negative metastatic breast cancer","volume":"13","author":"Hamilton","year":"2013","journal-title":"Clin. Breast Cancer"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3816\/CBC.2010.n.036","article-title":"Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer","volume":"10","author":"Conlin","year":"2010","journal-title":"Clin. Breast Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41416-019-0391-z","article-title":"A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients","volume":"120","author":"Fujiwara","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.drudis.2020.07.023","article-title":"Cancer stem cells and nanomedicine: New opportunities to combat multidrug resistance?","volume":"25","author":"Dalpiaz","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.febslet.2005.12.060","article-title":"The molecular basis of multidrug resistance in cancer: The early years of P-glycoprotein research","volume":"580","author":"Gottesman","year":"2006","journal-title":"FEBS Lett."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"31355","DOI":"10.1021\/acsami.0c20458","article-title":"Silicane derivative increases doxorubicin efficacy in an ovarian carcinoma mouse model: Fighting drug resistance","volume":"13","author":"Balvan","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Barbosa, G., Silva, P., Luz, G., and Brasil, L. (2015). Nanotechnology applied in drug delivery. Proceedings of the World Congress on Medical Physics and Biomedical Engineering, Toronto, ON, Canada, 7\u201312 June 2015, Springer.","DOI":"10.1007\/978-3-319-19387-8_222"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1021\/acs.nanolett.5b04221","article-title":"Cellular cargo delivery: Toward assisted fertilization by sperm-carrying micromotors","volume":"16","author":"Schwarz","year":"2016","journal-title":"Nano Lett."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"075501","DOI":"10.1103\/PhysRevLett.110.075501","article-title":"Sequence controlled self-knotting colloidal patchy polymers","volume":"110","author":"Coluzza","year":"2013","journal-title":"Phys. Rev. Lett."},{"key":"ref_152","first-page":"54","article-title":"Microbivores: Artificial mechanical phagocytes using digest and discharge protocol","volume":"14","author":"Freitas","year":"2005","journal-title":"J. Evol. Technol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1021\/nn800829k","article-title":"Can man-made nanomachines compete with nature biomotors?","volume":"3","author":"Wang","year":"2009","journal-title":"ACS Nano"},{"key":"ref_154","first-page":"44","article-title":"Nanobots: The future of medicine","volume":"5","author":"Bhat","year":"2014","journal-title":"Int. J. Manag. Eng. Sci."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-bioeng-071910-124724","article-title":"MRI-guided nanorobotic systems for therapeutic and diagnostic applications","volume":"13","author":"Vartholomeos","year":"2011","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"ref_156","first-page":"60","article-title":"Nanorobots: The future trend of drug delivery and therapeutics","volume":"10","author":"Asiwarya","year":"2011","journal-title":"Inter-Natl. J. Pharm. Sci. Rev. Res."},{"key":"ref_157","unstructured":"Freitas, R.A. (2009). Medical nanorobotics: The long-term goal for nanomedicine. Nanomedicine Design of Particles, Sensors, Motors, Implants, Robots and Devices, Artech House."},{"key":"ref_158","first-page":"20","article-title":"Role of nanotechnology in novel drug delivery system","volume":"1","author":"Bhowmik","year":"2009","journal-title":"J. Pharm. Sci. Technol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1166\/jnn.2006.413","article-title":"Pharmacytes: An ideal vehicle for targeted drug delivery","volume":"6","author":"Freitas","year":"2006","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2478\/s11536-012-0130-9","article-title":"Chemical robotics\u2014Chemotactic drug carriers","volume":"8","author":"Lagzi","year":"2013","journal-title":"Open Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.progsolidstchem.2005.11.009","article-title":"Nanotechnologies for drug delivery: Application to cancer and autoimmune diseases","volume":"34","author":"Couvreur","year":"2006","journal-title":"Prog. Solid. State Chem."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1038\/sj.onc.1209701","article-title":"Raf plus TGF\u03b2-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin","volume":"25","author":"Janda","year":"2006","journal-title":"Oncogene"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"eaaw2388","DOI":"10.1126\/scirobotics.aaw2388","article-title":"Catalytic antimicrobial robots for biofilm eradication","volume":"4","author":"Hwang","year":"2019","journal-title":"Sci. Robot."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"10712","DOI":"10.1021\/acsnano.7b04878","article-title":"The exosome total isolation chip","volume":"11","author":"Liu","year":"2017","journal-title":"ACS Nano"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jmmm.2018.08.048","article-title":"Magnetic drilling enhances intra-nasal transport of particles into rodent brain","volume":"469","author":"Jafari","year":"2019","journal-title":"J. Magn. Magn. Mater."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"9968","DOI":"10.1021\/acsnano.7b04128","article-title":"Magnetotactic bacteria powered biohybrids target E. coli biofilms","volume":"11","author":"Stanton","year":"2017","journal-title":"ACS Nano"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1002\/ange.201913872","article-title":"Onion-like Multifunctional Microtrap Vehicles for Attraction\u2013Trapping\u2013Destruction of Biological Threats","volume":"132","author":"Soto","year":"2020","journal-title":"Angew. Chem."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Lee, S., Kim Jy Kim, J., Hoshiar, A.K., Park, J., Lee, S., Kim, J., Pan\u00e9, S., Nelson, B.J., and Choi, H. (2020). A needle-type microrobot for targeted drug delivery by affixing to a microtissue. Adv. Healthc. Mater., 9.","DOI":"10.1002\/adhm.201901697"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1021\/am508621s","article-title":"Self-folding thermo-magnetically responsive soft microgrippers","volume":"7","author":"Breger","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1183\/09031936.01.00266101","article-title":"Chemotherapy in small cell lung cancer","volume":"18","year":"2001","journal-title":"Eur. Respir. J."},{"key":"ref_171","first-page":"3039","article-title":"Magnetic resonance pharmacoangiography to detect and predict chemotherapy delivery to solid tumors","volume":"61","author":"Artemov","year":"2001","journal-title":"Cancer Res."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"015103","DOI":"10.1088\/0957-4484\/19\/01\/015103","article-title":"Nanorobot architecture for medical target identification","volume":"19","author":"Cavalcanti","year":"2007","journal-title":"Nanotechnology"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/bit.25007","article-title":"Motility analysis of bacteria-based microrobot (bacteriobot) using chemical gradient microchamber","volume":"111","author":"Park","year":"2014","journal-title":"Biotechnol. Bioeng."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1021\/nn5011914","article-title":"Virus-inspired membrane encapsulation of DNA nanostructures to achieve in vivo stability","volume":"8","author":"Perrault","year":"2014","journal-title":"ACS Nano"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1369-7021(09)70157-9","article-title":"Nanofabrication by DNA self-assembly","volume":"12","author":"Li","year":"2009","journal-title":"Mater. Today"},{"key":"ref_176","first-page":"e29366","article-title":"The use of nanorobotics in the treatment therapy of cancer and its future aspects: A review","volume":"14","author":"Aggarwal","year":"2022","journal-title":"Cureus"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41578-020-00269-6","article-title":"Targeted drug delivery strategies for precision medicines","volume":"6","author":"Manzari","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e2204793","DOI":"10.1002\/advs.202204793","article-title":"A Magnetically Driven Amoeba-Like Nanorobot for Whole-Process Active Drug Transport","volume":"10","author":"Zhu","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1021\/acsnano.0c00959","article-title":"Magnetic measurement and stimulation of cellular and intracellular structures","volume":"14","author":"Wang","year":"2020","journal-title":"ACS Nano"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1021\/nl404815q","article-title":"Conformal cytocompatible ferrite coatings facilitate the realization of a nanovoyager in human blood","volume":"14","author":"Venugopalan","year":"2014","journal-title":"Nano Lett."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1039\/C4CC07644C","article-title":"Nanoparticle\u2013blood interactions: The implications on solid tumour targeting","volume":"51","author":"Lazarovits","year":"2015","journal-title":"Chem. Commun."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1039\/c3lc41423j","article-title":"Challenges of the movement of catalytic micromotors in blood","volume":"13","author":"Zhao","year":"2013","journal-title":"Lab. A Chip"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1166\/jbn.2019.2828","article-title":"DNA nanorobot delivers antisense oligonucleotides silencing c-Met gene expression for cancer therapy","volume":"15","author":"Zhang","year":"2019","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.2174\/0929867329666220821193938","article-title":"Nano\/microcarriers in drug delivery: Moving the timeline to contemporary","volume":"30","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Soto, F., Wang, J., Ahmed, R., and Demirci, U. (2020). Medical micro\/nanorobots in precision medicine. Adv. Sci., 7.","DOI":"10.1002\/advs.202002203"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"114854","DOI":"10.1016\/j.addr.2023.114854","article-title":"Design of disintegrable nanoassemblies to release multiple small-sized nanoparticles","volume":"197","author":"Zhu","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"e2200690","DOI":"10.1002\/adhm.202200690","article-title":"Advances in 3D bioprinting for cancer biology and precision medicine: From matrix design to application","volume":"11","author":"Jung","year":"2022","journal-title":"Adv. Healthc. Mater."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/5\/2109\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:16:40Z","timestamp":1772083000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/5\/2109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":187,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijms27052109"],"URL":"https:\/\/doi.org\/10.3390\/ijms27052109","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]}}}